publication venue for
- Relationship Between Social Support and Clinical Outcomes: An Evaluation of Participant-Nominated Treatment Supporters in the HOPE 4 Intervention. 17:e009342. 2024
- Letter by de Vries et al Regarding Article “Off-Label Under- and Overdosing of Direct Oral Anticoagulants in Patients With Atrial Fibrillation: A Meta-Analysis”. 15:e008982. 2022
- Accuracy of Cardiovascular Trial Outcome Ascertainment and Treatment Effect Estimates from Routine Health Data: A Systematic Review and Meta-Analysis. 14:e007903. 2021
- Kidney Function and Potassium Monitoring After Initiation of Renin-Angiotensin-Aldosterone System Blockade Therapy and Outcomes in 2 North American Populations. 13:e006415. 2020
- Abstract 290: Lessons Learned From Integrated Management Program Advancing Community Treatment Of Atrial Fibrillation (IMPACT-AF): A Pragmatic Clinical Trial Of Computerized Decision Support In Primary Healthcare. 13. 2020
- Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial. 12:e005858. 2019
- Cost-Effectiveness of Pharmacomechanical Catheter-Directed Thrombolysis Versus Standard Anticoagulation in Patients With Proximal Deep Vein Thrombosis. 12:e005659. 2019
- Abstract 198: Lifetime Clinical Benefit of Folic Acid Therapy for Primary Prevention of Stroke in Patients with Hypertension - Projection Based on the CSPPT. 12. 2019
- Sex-Specific Determinants of Outcomes After Transcatheter Aortic Valve Replacement. 12:e005363. 2019
- Gastrointestinal Bleeding With Edoxaban Versus Warfarin. 11:e003998. 2018
- Predicting the Benefits of Percutaneous Coronary Intervention on 1-Year Angina and Quality of Life in Stable Ischemic Heart Disease. 11:e003971. 2018
- Effectiveness of Quality Improvement Interventions at Reducing Inappropriate Cardiac Imaging. 9:7-13. 2016
- Does Sex Affect Anticoagulant Use for Stroke Prevention in Nonvalvular Atrial Fibrillation?. 8:S12-S20. 2015
- Frequency, Predictors, and Consequences of Crossing Over to Revascularization Within 12 Months of Randomization to Optimal Medical Therapy in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) Trial. 6:409-418. 2013
- Abstract 117: Application Of A Delphi Method To Develop A Patient Decision Aid For Implantable Cardioverter Defibrillator Candidates. 6. 2013
- Abstract 182: The Impact of National and Regional Health Systems Arrangements on Hypertension Awareness, Treatment and Control: a Systematic Literature Review. 6. 2013
- Abstract 189: Expressing Continuous Cardiovascular Outcome Data in Absolute Terms for use in Patient Treatment Decision Aids: Validation of a Proposed Method. 6. 2013
- Abstract 329: Barriers To Hypertension Screening, Treatment And Control As Reported By Patients And Healthcare Providers. 6. 2013
- Critical Care Cardiology Research. 6:237-242. 2013
- Comparison of Risk Factor Reduction and Tolerability of a Full-Dose Polypill (With Potassium) Versus Low-Dose Polypill (Polycap) in Individuals at High Risk of Cardiovascular Diseases. 5:463-471. 2012
- Radial Artery Versus Femoral Artery Access Options in Coronary Angiogram Procedures. 5:260-266. 2012
- Abstract 262: Speed and Distance Requirements for Community Ambulation: A Systematic Review. 5. 2012
- Abstract P131: Importance of Algorithm-Consistent Warfarin Dosing in the Quality of Anticoagulation Control in Atrial Fibrillation: A Multilevel Analysis. 4. 2011
- Abstract P192: The Gap Between Guidelines and Practice for the Total Cardiovascular Care of Atrial Fibrillation Patients in an Extended Study for Re-ly Patients Receiving Dabigatran. 4. 2011
- Abstract P199: Randomized Comparison of the DAWN AC Computer Program and a Simple Manual Nomogram for Quality of Warfarin Dosing. 4. 2011
- Abstract P200: Computerized Clinical Decision Support Systems for Therapeutic Drug Monitoring and Dosing: A Decision Maker--Researcher Partnership Systematic Review. 4. 2011
- Abstract P6: Vitamin K Antagonist Dosing Methods and Individual Patient Quality of INR Control in the International Active W Anticoagulation Study. 4. 2011
- Abstract P7: The Impact of Cardiovascular Hospitalization on Mortality and Quality of Life Among 14,261 Atrial Fibrillation Patients in the ACTIVE Study. 4. 2011
- A Meta-Analysis of Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, and Apolipoprotein B as Markers of Cardiovascular Risk. 4:337-345. 2011
- Physical Activity and the Risk of Incident Atrial Fibrillation in Women. 4:321-327. 2011
- The Cost-Effectiveness of Percutaneous Coronary Intervention as a Function of Angina Severity in Patients With Stable Angina. 4:172-182. 2011
- Age and Sex Differences and 20-Year Trends (1986 to 2005) in Prehospital Delay in Patients Hospitalized With Acute Myocardial Infarction. 3:590-598. 2010
- Enoxaparin Versus Dabigatran or Rivaroxaban for Thromboprophylaxis After Hip or Knee Arthroplasty. 3:652-660. 2010
- Do Major Cardiovascular Outcomes in Patients With Stable Ischemic Heart Disease in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Trial Differ by Healthcare System?. 3:476-483. 2010
- Factors Associated With Adverse Outcomes in Outpatients Presenting With Pulmonary Embolism. 3:390-394. 2010
- Cognitive Function and Anticoagulation Control in Patients With Atrial Fibrillation. 3:277-283. 2010
- Iatrogenic Adverse Events in the Coronary Care Unit. 2:437-442. 2009
- Quantitative Results of Baseline Angiography and Percutaneous Coronary Intervention in the COURAGE Trial. 2:320-327. 2009
- A 30-Year Perspective (1975–2005) Into the Changing Landscape of Patients Hospitalized With Initial Acute Myocardial Infarction. 2:88-95. 2009
- Paclitaxel Versus Sirolimus Stents in Diabetic and Nondiabetic Patients. 2:96-107. 2009
- Cost-Effectiveness of Percutaneous Coronary Intervention in Optimally Treated Stable Coronary Patients. 1:12-20. 2008